New combo treatment trial aims to help obese women reverse uterine condition and preserve fertility

This study tested whether adding a weight-loss drug (loxenatide) to a standard hormonal IUD treatment improves outcomes for obese women with a precancerous uterine condition called atypical endometrial hyperplasia. The goal was to see if helping patients lose weight could lead to better disease control and higher chances of preserving fertility. Thirty participants were randomly assigned to receive either the IUD alone or the IUD plus the weight-loss drug, and their progress was monitored for up to two years.